The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

The Medicine Foundry, which is expected to create 400 jobs, will be situated in the LEAP Research and Innovation District in ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...

PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded ...

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized ...

England's National Health Services plans to offer Eli Lilly's weight-loss drugs to nearly a quarter million people as part of ...

The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list ...

Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.